{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:06:44Z","timestamp":1783015604922,"version":"3.54.6"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"DOI":"10.1186\/s12962-025-00651-7","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T12:52:18Z","timestamp":1756471938000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-effectiveness analysis of a community pharmacist-based intervention to prevent cardiovascular complications in patients with type 2 diabetes in Iran"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7920-3262","authenticated-orcid":false,"given":"Zahra","family":"Ghasemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1788-0281","authenticated-orcid":false,"given":"Rimal","family":"Mousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2841-0808","authenticated-orcid":false,"given":"Farzad","family":"Peiravian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8079-7424","authenticated-orcid":false,"given":"Nazila","family":"Yousefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"651_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108072","author":"R Williams","year":"2020","unstructured":"Williams R, Karuranga S, Malanda B, Saeedi P, Basit A, Besan\u00e7on S, et al. Global and regional estimates and projections of diabetes-related health expenditure: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2020. https:\/\/doi.org\/10.1016\/j.diabres.2020.108072.","journal-title":"Diabetes Res Clin Pract"},{"issue":"July","key":"651_CR2","first-page":"1","volume":"1","author":"RA DeFronzo","year":"2015","unstructured":"DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015;1(July):1\u201323.","journal-title":"Nat Rev Dis Primers"},{"issue":"1\u20132","key":"651_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2991\/j.jegh.2017.11.004","volume":"8","author":"EM Onyango","year":"2018","unstructured":"Onyango EM, Onyango BM. The rise of noncommunicable diseases in Kenya: an examination of the time trends and contribution of the changes in diet and physical inactivity. J Epidemiol Glob Health. 2018;8(1\u20132):1\u20137.","journal-title":"J Epidemiol Glob Health"},{"key":"651_CR4","unstructured":"Report W, Diabetes. 2021;(November):1\u20135."},{"key":"651_CR5","unstructured":"Beckman J. IDF Diabetes Atlas. Vol. 76, Offshore. 2016. 1 p."},{"issue":"5","key":"651_CR6","first-page":"493","volume":"22","author":"S Pousinho","year":"2016","unstructured":"Pousinho S, Morgado M, Falc\u00e3o A, Alves G. Pharmacist interventions in the management of type 2 diabetes mellitus: a systematic review of randomized controlled trials. J Manag Care Spec Pharm. 2016;22(5):493\u2013515.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1138","key":"651_CR7","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1136\/postgradmedj-2020-137511","volume":"96","author":"S Brewster","year":"2020","unstructured":"Brewster S, Holt R, Portlock J, Price H. The role of community pharmacists and their position in the delivery of diabetes care: an update for medical professionals. Postgrad Med J. 2020;96(1138):473\u20139.","journal-title":"Postgrad Med J"},{"issue":"2","key":"651_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.4321\/S1886-36552010000200001","volume":"8","author":"S Clifford","year":"2010","unstructured":"Clifford S, Garfield S, Eliasson L, Barber N. Medication adherence and community pharmacy: a review of education, policy and research in England. Pharm Pract (Granada). 2010;8(2):77\u201388.","journal-title":"Pharm Pract (Granada)"},{"key":"651_CR9","first-page":"137","volume":"6","author":"DA Erku","year":"2017","unstructured":"Erku DA, Belachew SA, Mekuria AB, Taye Haile K, Gebresillassie BM, Tegegn HG, et al. The role of community pharmacists in patient counseling and health education: a survey of their knowledge and level of involvement in relation to type 2 diabetes mellitus. Integr Pharm Res Pract. 2017;6:137\u201343.","journal-title":"Integr Pharm Res Pract"},{"issue":"6","key":"651_CR10","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/jcpt.12700","volume":"43","author":"MYL Siaw","year":"2018","unstructured":"Siaw MYL, Malone DC, Ko Y, Lee JYC. Cost-effectiveness of multidisciplinary collaborative care versus usual care in the management of high-risk patients with diabetes in Singapore: short-term results from a randomized controlled trial. J Clin Pharm Ther. 2018;43(6):775\u201383.","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"651_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0195898","volume":"13","author":"WC Wu","year":"2018","unstructured":"Wu WC, Taveira TH, Jeffery S, Jiang L, Tokuda L, Musial J, et al. Costs and effectiveness of pharmacist-led group medical visits for type-2 diabetes: A multi-center randomized controlled trial. PLoS ONE. 2018;13(4):1\u201314.","journal-title":"PLoS ONE"},{"key":"651_CR12","unstructured":"World Health Organization. WHO, Cardiovascular diseases [Internet]. 2022. Available from: https:\/\/www.who.int\/health-topics\/cardiovascular-diseases#tab=tab_1"},{"issue":"9","key":"651_CR13","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-013-2940-y","volume":"56","author":"AJ Hayes","year":"2013","unstructured":"Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year united Kingdom prospective diabetes study: UKPDS 82. Diabetologia. 2013;56(9):1925\u201333.","journal-title":"Diabetologia"},{"issue":"3","key":"651_CR14","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ejim.2012.11.014","volume":"24","author":"H Khalili","year":"2013","unstructured":"Khalili H, Karimzadeh I, Mirzabeigi P, Dashti-Khavidaki S. Evaluation of clinical pharmacist\u2019s interventions in an infectious diseases ward and impact on patient\u2019s direct medication cost. Eur J Intern Med. 2013;24(3):227\u201333.","journal-title":"Eur J Intern Med"},{"issue":"4","key":"651_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1046\/j.1524-4733.2003.64255.x","volume":"6","author":"LR Etemad","year":"2003","unstructured":"Etemad LR, Hay JW. Cost-effectiveness analysis of pharmaceutical care in a medicare drug benefit program. Value Health. 2003;6(4):425\u201335.","journal-title":"Value Health"},{"key":"651_CR16","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.diabres.2017.09.002","volume":"132","author":"P Aschner","year":"2017","unstructured":"Aschner P. New IDF clinical practice recommendations for managing type 2 diabetes in primary care. Diabetes Res Clin Pract. 2017;132:169\u201370.","journal-title":"Diabetes Res Clin Pract"},{"key":"651_CR17","unstructured":"IDF. Key Information of DM in Iran [Internet]. 2021. Available from: https:\/\/idf.org\/our-network\/regions-and-members\/middle-east-and-north-africa\/members\/iran\/"},{"key":"651_CR18","unstructured":"Gabric Diabetes Education Association. Gabric Diabetes Education Association."},{"issue":"5","key":"651_CR19","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1080\/14737167.2021.1838900","volume":"21","author":"R Mousa","year":"2021","unstructured":"Mousa R, Hammad E. Cost-effectiveness of pharmacist-led care versus usual care in type 2 diabetic Jordanians: a Markov modeling of cardiovascular diseases prevention. Expert Rev Pharmacoecon Outcomes Res. 2021;21(5):1069\u201379. https:\/\/doi.org\/10.1080\/14737167.2021.1838900.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"651_CR20","first-page":"121","volume":"15","author":"YMD Bayazidi","year":"2020","unstructured":"Bayazidi YMD. The Estimation of the Imposed Economic Burden Due to Inadequate Medical Care in Patients Suffering from Type 2 Diabetes in Tehran. Tamin Ejtemaei. 2020;15(1):121\u201331.","journal-title":"Tamin Ejtemaei"},{"issue":"1","key":"651_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/pharmacy7010030","volume":"7","author":"D Wright","year":"2019","unstructured":"Wright D, Little R, Turner D, Thornley T. Diabetes screening through community pharmacies in England: a cost-effectiveness study. Pharmacy. 2019;7(1):30.","journal-title":"Pharmacy"},{"issue":"6","key":"651_CR22","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10935-014-0368-x","volume":"35","author":"D Hendrie","year":"2014","unstructured":"Hendrie D, Miller TR, Woodman RJ, Hoti K, Hughes J. Cost-effectiveness of reducing glycaemic episodes through community pharmacy management of patients with type 2 diabetes mellitus. J Prim Prev. 2014;35(6):439\u201349.","journal-title":"J Prim Prev"},{"issue":"2","key":"651_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1331\/108658003321480696","volume":"43","author":"CW Cranor","year":"2003","unstructured":"Cranor CW, Christensen DB. The Asheville project: short-term outcomes of a community pharmacy diabetes care program. J Am Pharm Association (1996). 2003;43(2):149\u201359.","journal-title":"J Am Pharm Association (1996)"},{"issue":"9","key":"651_CR24","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1464-5491.2012.03725.x","volume":"29","author":"M Ali","year":"2012","unstructured":"Ali M, Schifano F, Robinson P, Phillips G, Doherty L, Melnick P, et al. Impact of community pharmacy diabetes monitoring and education programme on diabetes management: A randomized controlled study. Diabet Med. 2012;29(9):326\u201333.","journal-title":"Diabet Med"},{"issue":"03","key":"651_CR25","doi-asserted-by":"publisher","first-page":"124","DOI":"10.4236\/pp.2016.73016","volume":"07","author":"H Okada","year":"2016","unstructured":"Okada H, Onda M, Shoji M, Kotani K, Nakayama T, Nakagawa Y, et al. Effects of lifestyle intervention performed by community pharmacists on glycemic control in patients with type 2 diabetes: the community pharmacists assist (Compass) project, a pragmatic cluster randomized trial. Pharmacol Pharm. 2016;07(03):124\u201332.","journal-title":"Pharmacol Pharm"},{"key":"651_CR26","unstructured":"Nima Motamed, Zamani F. Sample size in medical and clinical assessments. 1395. 284 p."},{"key":"651_CR27","first-page":"1","volume":"34","author":"H Ameri","year":"2020","unstructured":"Ameri H, Safari H, Yousefi M, faradonbeh SB, Goudarzi R, Soofi M. Interim value set for the EQ-5D-5L in Iran using the crosswalk method. Med J Islam Repub Iran. 2020;34:1\u20135.","journal-title":"Med J Islam Repub Iran"},{"issue":"5","key":"651_CR28","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1080\/14737167.2021.1838900","volume":"21","author":"R Mousa","year":"2021","unstructured":"Mousa R, Hammad E. Cost-effectiveness of pharmacist-led care versus usual care in type 2 diabetic Jordanians: a Markov modeling of cardiovascular diseases prevention. Expert Rev Pharmacoecon Outcomes Res. 2021;21(5):1069\u201379.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"651_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40008-018-0127-x","volume":"7","author":"A Daneshmand","year":"2018","unstructured":"Daneshmand A, Jahangard E, Abdollah-Milani M. A time preference measure of the social discount rate for Iran. J Econ Struct. 2018;7(1):29. https:\/\/doi.org\/10.1186\/s40008-018-0127-x.","journal-title":"J Econ Struct"},{"issue":"4","key":"651_CR30","doi-asserted-by":"publisher","first-page":"766","DOI":"10.2337\/dci21-0064","volume":"45","author":"K Khunti","year":"2022","unstructured":"Khunti K, Aroda VR. Coming full circle: prioritizing early glycemic control to reduce microvascular and macrovascular complications in people with type 2 diabetes. Diabetes Care. 2022;45(4):766\u20138.","journal-title":"Diabetes Care"},{"issue":"6","key":"651_CR31","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s13300-022-01253-9","volume":"13","author":"M Evans","year":"2022","unstructured":"Evans M, Welsh Z, Seibold A. Reductions in HbA1c with flash glucose monitoring are sustained for up to 24 months: a meta-analysis of 75 real-world observational studies. Diabetes Ther. 2022;13(6):1175\u201385.","journal-title":"Diabetes Ther"},{"key":"651_CR32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.vhri.2020.04.004","volume":"24","author":"MS Movahed","year":"2021","unstructured":"Movahed MS, Barghazan SH, Adel A, Rezapour A. Economic burden of stroke in Iran: a population-based study. Value Health Reg Issues. 2021;24:77\u201381.","journal-title":"Value Health Reg Issues"},{"issue":"2","key":"651_CR33","doi-asserted-by":"publisher","first-page":"e1120","DOI":"10.1002\/hsr2.1120","volume":"6","author":"H Jalilian","year":"2023","unstructured":"Jalilian H, Heydari S, Imani A, Salimi M, Mir N, Najafipour F. Economic burden of type 2 diabetes in Iran: a cost-of-illness study. Health Sci Rep. 2023;6(2):e1120. https:\/\/doi.org\/10.1002\/hsr2.1120.","journal-title":"Health Sci Rep"},{"issue":"4","key":"651_CR34","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/jcpt.12536","volume":"42","author":"MYL Siaw","year":"2017","unstructured":"Siaw MYL, Ko Y, Malone DC, Tsou KYK, Lew YJ, Foo D, et al. Impact of pharmacist-involved collaborative care on the clinical, humanistic and cost outcomes of high-risk patients with type 2 diabetes (IMPACT): a randomized controlled trial. J Clin Pharm Ther. 2017;42(4):475\u201382.","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"651_CR35","first-page":"102","volume":"19","author":"J Yu","year":"2013","unstructured":"Yu J, Shah BM, Ip EJ, Chan J. A markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California. J Manag Care Pharm. 2013;19(2):102\u201314.","journal-title":"J Manag Care Pharm"},{"issue":"3","key":"651_CR36","first-page":"131","volume":"15","author":"N Khunti","year":"2013","unstructured":"Khunti N, Willis A, Davies M, Khunti K. The role of pharmacists in the management of type 2 diabetes: a literature review. Diabetes Prim Care. 2013;15(3):131\u201340.","journal-title":"Diabetes Prim Care"},{"issue":"1","key":"651_CR37","first-page":"029","volume":"8","author":"M Mehrpooya","year":"2018","unstructured":"Mehrpooya M, Larki-Harchegani A, Ahmadimoghaddam D, Kalvandi M, Mohammadi Y, Javad MT, et al. Evaluation of the effect of education provided by pharmacists on hyperlipidemic patient\u2019s adherence to medications and blood level of lipids. J Appl Pharm Sci. 2018;8(1):029\u201333.","journal-title":"J Appl Pharm Sci"},{"issue":"1","key":"651_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18549\/PharmPract.2017.01.846","volume":"15","author":"BC Loh","year":"2017","unstructured":"Loh BC, Wah KF, Teo CA, Khairuddin NM, Fairuz FB, Liew JE. Impact of value added services on patient waiting time at the ambulatory pharmacy Queen Elizabeth Hospital. Pharm Pract (Granada). 2017;15(1):1\u20137.","journal-title":"Pharm Pract (Granada)"},{"issue":"6","key":"651_CR39","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1080\/14737167.2016.1259071","volume":"16","author":"A Malet-Larrea","year":"2016","unstructured":"Malet-Larrea A, Garc\u00eda-C\u00e1rdenas V, S\u00e1ez-Benito L, Benrimoj S, Calvo B, Goyenechea E. Cost-effectiveness of professional pharmacy services in community pharmacy: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2016;16(6):747\u201358. https:\/\/doi.org\/10.1080\/14737167.2016.1259071.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"651_CR40","first-page":"15","volume":"6","author":"J Hughes","year":"2017","unstructured":"Hughes J, Wibowo Y, Sunderland B, Hoti K. The role of the pharmacist in the management of type 2 diabetes: current insights and future directions. Integr Pharm Res Pract. 2017;6:15\u201327.","journal-title":"Integr Pharm Res Pract"},{"issue":"1","key":"651_CR41","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3111\/13696990903479199","volume":"13","author":"L Breitscheidel","year":"2010","unstructured":"Breitscheidel L, Stamenitis S. Economic impact of compliance to treatment with antidiabetes medication in type 2 diabetes mellitus: a review paper. J Med Econ. 2010;13(1):8\u201315.","journal-title":"J Med Econ"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00651-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-025-00651-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00651-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T05:30:24Z","timestamp":1757482224000},"score":1,"resource":{"primary":{"URL":"https:\/\/resource-allocation.biomedcentral.com\/articles\/10.1186\/s12962-025-00651-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["651"],"URL":"https:\/\/doi.org\/10.1186\/s12962-025-00651-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5788534\/v1","asserted-by":"object"}]},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was carried out using the principles of good clinical practice and the Declaration of Helsinki. The Shahid Beheshti University of Medical Science\u2019s ethics committee approved this service trial study (IR.SMBU.PHARMACY.REC.1400.450). Written informed consent was obtained from each participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}